Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 12/20 | 0.51 |
| ▸ | CNR1 | P21554 | 6/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19785562 | 0.90 | PTPN11 (0.65) | PTPN11CNR1KCNH2MAPK3MAPK1 | |
| SCHEMBL25514610 | 0.88 | PTPN11 (0.47) | PTPN11CNR1KCNH2MAPK3MAPK1 | |
| SCHEMBL25514611 | 0.86 | PTPN11 (0.51) | PTPN11CNR1KCNH2MAPK3MAPK1 | |
| SCHEMBL25514363 | 0.85 | PTPN11 (0.41) | PTPN11CNR1KCNH2MAPK3MAPK1 | |
| SCHEMBL25514613 | 0.82 | PTPN11 (0.42) | PTPN11KCNH2MAPK3MAPK1KDM4E | |
| SCHEMBL21154427 | 0.80 | PTPN11 (0.59) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL25514349 | 0.80 | PTPN11 (0.53) | PTPN11CNR1KCNH2MAPK3MAPK1 | |
| SCHEMBL23425267 | 0.78 | PTPN11 (0.43) | PTPN11CNR1KCNH2MAPK3MAPK1 | |
| SCHEMBL19651432 | 0.78 | PTPN11 (0.55) | PTPN11 | |
| SCHEMBL25514287 | 0.78 | PTPN11 (0.65) | PTPN11KCNH2MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN22, PTPN2 | PTPN11 8/4885CNR1 4035/4885KCNH2 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.